Newswise — Stanford University researchers stated they are developing a blood test that could be used to identify patients with Alzheimer's disease, according to a paper published by the British journal, Nature Medicine. For those covering today's news, Power3 Medical Products, Inc. makes available Dr. Ira Goldknopf, director of proteomics of Power3 Medical Products, Inc., and leading researcher in proteomics. Dr. Goldknopf believes that while this news is encouraging, the science of proteomics has already produced a simple blood test for Alzheimer's. Power3 is in the forefront of proteomic testing, including the development of NuroPro®, Power3's diagnostic tool for the early detection of neurodegenerative diseases. Currently in pre-commercialization development, NuroPro® recently concluded a validation study.
Biography on ExpertDr. Goldknopf has over thirty years of proteomic experience. He is a well-recognized pioneer and leader in Proteomics, having produced the first isolation, identification, and sequencing of a new protein spot on a 2D gel, which was the first discovery of ubiquitin conjugation of proteins and which laid the groundwork for the 2000 Lasker Award and the 2004 Nobel Prize in Chemistry. Dr. Goldknopf spent ten years on the faculty of Baylor College of Medicine and a sabbatical year at the Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden. He is the author of more than seventy publications and also serves on the Scientific Advisory Board of the Company.
Dr. Ira Goldknopf, Director of Proteomics of Power3 Medical Products, serves as an expert resource on the following:
"¢ The diagnosis and treatment of neurodegenerative diseases."¢ Proteomics research and applications. "¢ Blood-based diagnostic testing.
Dr. Goldknopf can address the following FAQs:"¢ What is proteomics? How do proteomics tests differ from genetic tests?"¢ How is Alzheimer's detected in the blood?"¢ Can memory loss later in life be predicted?"¢ What about other diseases like Parkinson's and ALS (Lou Gehrig's disease)"¢ How can protein biomarkers be used to test for neurodegenerative diseases?"¢ What is the current gold standard of neurodegenerative disease diagnosis?"¢ Can proteomics play a role, not just in testing, but also more effective treatment options?
Power3 Medical Products, Inc., is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM) of Fort Myers, Florida, to commercialize Power3's portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer's and Parkinson's Diseases.
RSS